Lipoxin A4-d5

Lipoxin A4-d5

• CAS Number: 1622429-53-1
• UNSPSC Description: Lipoxin A4-d5 is the deuterium labeled Lipoxin A4. Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties[1]. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways[2]. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM[3].
• Target Antigen: Endogenous Metabolite; Interleukin Related
• Type: Isotope-Labeled Compounds
• Related Pathways: Immunology/Inflammation;Metabolic Enzyme/Protease
• Field of Research: Inflammation/Immunology
• Solubility: 10 mM in DMSO
• Smiles: O[C@H](/C=C/C=C\C=C\C=C\[C@H]([C@H](CCCC(O)=O)O)O)CCCC([2H])(C([2H])([2H])[2H])[2H]
• Molecular Weight: 357.50
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Feng Hu, et al. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes associated with the ERK1/2 and NF-κB pathways. J Dermatol Sci. 2015 Jun;78(3):181-8.|[3]Steven Bozinovski, et al. Serum amyloid A opposes lipoxin A₄ to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A. 2012 Jan 17;109(3):935-40.|[4]Xinxin Liu, et al. Lipoxin A4 and its analog suppress inflammation by modulating HMGB1 translocation and expression in psoriasis.Sci Rep. 2017 Aug 2;7(1):7100.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported